FibroBiologics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBLG research report →
About the company
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
- CEO
- Peter O'Heeron
- IPO
- 2024
- Employees
- 13
- HQ
- Houston, DE, US
Price Chart
- Market Cap
- $1.84M
- P/E
- -0.11
- P/S
- 0.00
- P/B
- 0.75
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -767.07%
- ROIC
- -338.44%
- Revenue
- $0 · 0.00%
- Net Income
- $-18,646,000 · -67.06%
- EPS
- $-8.40 · -23.53%
- Op Income
- $-16,649,000
- FCF YoY
- -37.82%
- 52W High
- $14.68
- 52W Low
- $0.73
- 50D MA
- $1.07
- 200D MA
- $5.04
- Beta
- 1.15
- Avg Volume
- 259.37K
Get TickerSpark's AI analysis on FBLG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 23, 26 | Hoffman Robert E. | other | 30,803 |
| Jun 23, 26 | Cilento Richard C. Jr. | other | 30,803 |
| Jun 23, 26 | Link Matthew | other | 30,803 |
| Jun 23, 26 | Niklas Victoria Ninon Olivia | other | 30,803 |
| May 4, 26 | O'HEERON PETE | other | 92,410 |
| May 4, 26 | Khoja Hamid | other | 61,607 |
| May 4, 26 | Davis Jason | other | 61,607 |
| May 4, 26 | GARCIA RUBEN A | other | 61,607 |
| Mar 4, 26 | Khoja Hamid | buy | 30,000 |
| Mar 4, 26 | O'HEERON PETE | buy | 15,872 |
Our FBLG coverage
Recent articles, reports, and earnings notes.
No research on FBLG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FBLG report →Similar companies
Peers in the same neighborhood.